Abstract 2323
Background
It is well documented that survival of CRC is dependent on early diagnosis. In England, the Department of Health’s cancer policy states that patients with symptoms of suspected cancer must be seen and assessed by the specialist team within 2 weeks of a referral by their General Practitioner (GP). The traditional 2 week wait (2ww) referral route involves these patients being seen in clinic within 2 weeks, where they are assessed and an investigation is booked, taking up to 4 weeks for first investigation and diagnosis. We have introduced a novel Straight to Test / CTAP for these patients, which rationalises the patient journey, ensuring that the patient has the right test first time, without delay.
Methods
Our service is a Consultant Nurse led Straight to Test / CTAP. All 2ww patients referred by the GP with suspected CRC are assessed via the CTAP. Upon receipt of the electronic referral from their GP, a colorectal assessment is carried out via telephone within 48 hours of referral by the Consultant nurse or a member or her specialist nursing team. The patient is then triaged for the most appropriate investigation, according to a protocol, which is then booked within 2 weeks of the GPs referral.
Results
The CTAP has been running now for 5 years with over 4000 patients being assessed via this route. In 2017 & 2018 the cancer yield from our service was 4% which matches that of traditional out-patient assessments routes. However we were able to reduce the patient pathway by 10 days by the introduction of the CTAP. 70% of patients had an endoscopy procedure as their first investigation and 28% had a radiological investigation (usually CT Colonography). 90% of patients had their diagnosis or given the all clear by day 14.
Conclusions
This pathway has significantly shortened the patient’s pathway and time diagnosis for our patients, meaning that those patients with CRC are diagnosed by day 14. Patients with other pathologies are also diagnosed quicker and those patients with no serious pathology are reassured and discharged back to their GP We have managed to reduce waiting times from referral to diagnosis and to ensure all patients on the 2ww pathway have a more streamline patient focused experience, avoiding unnecessary hospital visits.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract